Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lantheus Biosciences Ltd.
Age
35–75
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
In Germany Healthy volunteers
Males/females ≥ 50 and ≤ 65 years Patients
Males/females ≥ 35 and ≤ 75 years
histologically confirmed diagnosis of non small cell lung cancer or adenocarcinoma of the breast with a positive FDG-PET or
patient with primary prostate cancer scheduled for prostatectomy and patient with prostate tumor recurrence with a positive choline-PET, the initial disease is histologically confirmed or
inflammation with a positive FDG-PET
In Korea Patients
Males/females ≥ 35 and ≤ 75 years
histologically confirmed diagnosis of non small cell lung cancer, adenocarcinoma of the breast or hepatocellular cancer with a positive FDG-PET or
patient with primary prostate cancer scheduled for prostatectomy and patient with prostate tumor recurrence with a positive choline-PET, the initial disease is histologically confirmed or
inflammation (positive FDG-PET mandatory, could be also done as screening examination)
You may not be if
Concurrent severe and/or uncontrolled and/or unstable medical disease other than cancer or inflammation (e.g. poorly controlled diabetes, congestive heart failure, myocardial infarction within 12 months prior to planned injection of BAY 94-9392, unstable and uncontrolled hypertension, chronic renal or hepatic disease, severe pulmonary disease) which could compromise participation in the study
Known sensitivity to the study drug or components of the preparation
Clareo Health | Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation
